Search research articles
Contact Us
Filters
Showing results (521-530 of 659) with videos related to
Page
of 66
Sort By:
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Hagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Leukemia
|
April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology
|
April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis
Elias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology
|
July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure
Samuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Page
of 66
Search research articles
Search
Showing results (521-530 of 659) with videos related to
Sort By:
Page
of 66
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Hagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Leukemia
|
April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology
|
April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis
Elias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology
|
July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure
Samuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Page
of 66